Cyclo Therapeutics, Inc. (CYTH) Net Income (Loss) Attributable to Parent USD 2012 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cyclo Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2012 to 2024.
  • Cyclo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$4.34 M, a 13.3% increase year-over-year.
  • Cyclo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$19.4 M, a 9.65% decline year-over-year.
  • Cyclo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$20.1 M, a 29.8% decline from 2022.
  • Cyclo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$15.5 M, a 8.15% decline from 2021.
  • Cyclo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$14.3 M, a 59.8% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$19.4 M -$4.34 M +$664 K +13.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$20.1 M -$5.64 M -$662 K -13.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-18
Q3 2023 -$19.4 M -$4.77 M -$524 K -12.4% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$18.9 M -$4.64 M -$1.18 M -34.3% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 -$17.7 M -$5.01 M -$2.24 M -80.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$15.5 M -$4.98 M -$2.19 M -78.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-18
Q3 2022 -$13.3 M -$4.25 M -$387 K -10% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$12.9 M -$3.45 M +$145 K +4.04% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$13 M -$2.77 M +$1.27 M +31.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$14.3 M -$2.79 M -$113 K -4.21% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-17
Q3 2021 -$14.2 M -$3.86 M -$2.42 M -169% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$11.7 M -$3.6 M -$1.41 M -64.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$10.3 M -$4.04 M -$1.4 M -53.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$8.94 M -$2.68 M -$44.6 K -1.69% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 -$8.9 M -$1.44 M +$190 K +11.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$9.09 M -$2.19 M -$824 K -60.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$8.26 M -$2.63 M -$730 K -38.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
Q4 2019 -$7.53 M -$2.64 M -$1.27 M -93% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$6.26 M -$1.63 M -$838 K -106% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$5.43 M -$1.37 M -$78.8 K -6.11% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 -$5.35 M -$1.9 M -$1.09 M -134% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
Q4 2018 -$4.26 M -$1.37 M +$18.5 K +1.34% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 -$4.27 M -$787 K -$154 K -24.2% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$4.12 M -$1.29 M -$461 K -55.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-14
Q1 2018 -$3.66 M -$813 K +$175 K +17.7% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-14
Q4 2017 -$3.83 M -$1.38 M -$552 K -66.4% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-15
Q3 2017 -$3.28 M -$634 K +$981 K +60.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$4.26 M -$828 K +$243 K +22.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$4.51 M -$987 K -$282 K -39.9% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q4 2016 -$4.22 M -$832 K +$223 K +21.2% Oct 1, 2016 Dec 31, 2016 10-K 2018-04-16
Q3 2016 -$4.45 M -$1.61 M -$867 K -116% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 -$3.58 M -$1.07 M -$711 K -197% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-11
Q1 2016 -$2.87 M -$706 K -$318 K -81.8% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
Q4 2015 -$2.55 M -$1.06 M -$738 K -233% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-17
Q3 2015 -$1.81 M -$748 K -$527 K -238% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 -$1.29 M -$360 K -$209 K -138% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-12
Q1 2015 -$1.08 M -$388 K -$485 K -501% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-16
Q4 2014 -$593 K -$317 K -$233 K -276% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-30
Q3 2014 -$360 K -$221 K -$126 K -134% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 -$233 K -$151 K -$415 K -157% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-14
Q1 2014 $182 K $96.9 K -$23.2 K -19.3% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-15
Q4 2013 $205 K -$84.4 K -$215 K -165% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-27
Q3 2013 $420 K -$94.5 K -$48.8 K -107% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-14
Q2 2013 $469 K $264 K +$320 K Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-14
Q1 2013 $149 K $120 K +$74.3 K +162% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-09
Q4 2012 $74.2 K $131 K Oct 1, 2012 Dec 31, 2012 10-K 2014-03-04
Q3 2012 -$45.7 K Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-13
Q2 2012 -$56.4 K Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-14
Q1 2012 $45.8 K Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.